IPO registrations (S-1, F-1) · Registrants
Icagen, Inc.
- SEC CIK
- 1518520 · filings on EDGAR ↗
- Name on the registration
- XRpro Sciences, Inc.
- Former names
- XRpro Sciences, Inc. (2014–2015); Caldera Pharmaceuticals Inc (2011–2014)
- Registration
- Form S-1, first filed 2012-02-14, last 2015-05-11; 2 initial registrations, 5 amendments
- Outcome
- Declared effective 2012-07-05
- Industry (SIC)
- Services-Commercial Physical & Biological Research 8731
- Incorporated in
- DE
- Business address
- 4222 EMPEROR BLVD., SUITE 350, RESEARCH TRIANGLE PARK, Durham, NC 27703
- EIN
- 20-0982060
- EDGAR entity type
- operating
- Insiders and CEO pay
- Icagen, Inc. on the corporate pages
Offering terms
- Shares offered
- 2,069,525
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: ICAGEN, INC. EXACT (EIN (EXACT))
- Federal award recipient: ICAGEN, INC. Fuzzy (name and state)
- Form D issuer: Icagen, Inc. EXACT (CIK (EXACT))
- SEC filer: Caldera Pharmaceuticals Inc EXACT (CIK (EXACT))
Filings 9
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2012-02-14 | S-1 | S-1 (registration) | Caldera Pharmaceuticals Inc | 0001213900-12-000691 ↗ |
| 2012-04-20 | S-1/A | S-1/A (amendment) | Caldera Pharmaceuticals Inc | 0001213900-12-001987 ↗ |
| 2012-06-08 | S-1/A | S-1/A (amendment) | Caldera Pharmaceuticals Inc | 0001213900-12-003228 ↗ |
| 2012-06-22 | S-1/A | S-1/A (amendment) | Caldera Pharmaceuticals Inc | 0001213900-12-003455 ↗ |
| 2012-06-28 | S-1/A | S-1/A (amendment) | Caldera Pharmaceuticals Inc | 0001213900-12-003547 ↗ |
| 2012-07-05 | EFFECT | EFFECT (declared effective) | Caldera Pharmaceuticals Inc | 9999999995-12-002061 ↗ |
| 2015-04-21 | S-1 | S-1 (registration) | XRpro Sciences, Inc. | 0001213900-15-002895 ↗ |
| 2015-05-11 | S-1/A | S-1/A (amendment) | XRpro Sciences, Inc. | 0001213900-15-003468 ↗ |
| 2015-05-14 | EFFECT | EFFECT (declared effective) | XRpro Sciences, Inc. | 9999999995-15-001347 ↗ |
Prospectus pages read 1
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2015-05-11 | S-1/A | registration statement | $3.50 | 2,069,525 | $7,243,337 | 0 | primary document; price sentence, shares headline, proceeds computed | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Roffman Edward | Director | 7 | 2012–2018 | ||
| Warner Benjamin | Director; Director,Officer,TenPercentOwner | Chief Scientific Officer; President and CEO | 4 | 2012–2015 | |
| Zimmerman Frank Jeremiel | Director | 1 | 2012 | ||
| KABATZNIK CLIVE | Director | 8 | 2013–2018 | ||
| Palmieri Vincent | Director | 15 | 2013–2018 | ||
| TAGLICH MICHAEL N | Director; Director,TenPercentOwner | 17 | 2013–2019 | ||
| Altman Gary | Director,Officer; Officer | President and CEO | 2 | 2013 | |
| KORB MARK JOHN | Officer | Chief Financial Officer | 2 | 2013–2018 | |
| TYSON TIMOTHY | Director; Director,TenPercentOwner | 12 | 2014–2018 | ||
| Cunningham, Richard Anthony | Officer | Chief Executive Officer; President and CEO | 6 | 2014–2019 | |
| Krafte Douglas | Officer | Chief Scientific Officer | 4 | 2016–2019 | |
| TAGLICH ROBERT | Director,TenPercentOwner; TenPercentOwner | 5 | 2017–2019 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2018-09-12 | Icagen, Inc. | Pharmaceuticals | $7,250,000 | $7,250,000 | 1 | 1 |
| 2018-08-15 | Icagen, Inc. | Pharmaceuticals | $1,500,000 | $500,000 | 4 | 1 |
| 2018-04-12 | Icagen, Inc. | Pharmaceuticals | $4,000,000 | $2,000,000 | 1 | 1 |
| 2017-05-25 | Icagen, Inc. | Biotechnology | $2,000,000 | $2,000,000 | 1 | 1 |
| 2017-04-28 | Icagen, Inc. | Pharmaceuticals | $1,500,000 | $1,500,000 | 3 | 1 |
| 2016-07-08 | Icagen, Inc. | Pharmaceuticals | $1,145,000 | $1,145,000 | 12 | 1 |
| 2014-12-16 | XRpro Sciences, Inc. | Pharmaceuticals | $8,855,000 | $8,855,000 | 162 | 2 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | Icagen, Inc. | NC | Form D private offerings | CIK (EXACT) |
| SEC filer | Icagen, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Form 5500 plan sponsor | ICAGEN, INC. | EIN (EXACT) | ||
| Federal award recipient | ICAGEN, INC. | Federal spending (USAspending) | name and state |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Services-Commercial Physical & Biological Research, NC first:
- Icoria, Inc. NC
- INVERESK RESEARCH GROUP INC NC
- PRA International, LLC NC
- IQVIA HOLDINGS INC. NC
- Syneos Health, Inc. NC
- PRA Health Sciences, Inc. NC
- PPD, Inc. NC
- Science 37 Holdings, Inc. NC
- WEED, INC. AZ
- GLYCOTEX, INC. C3
In other datasets, the same topic (Medical research) in NC:
- Form D issuer: 22nd Century Group, Inc. (Form D private offerings)
- Nonprofit: 3000 MILES FOR AUTISM (Nonprofits (IRS Form 990))
Interests: Services-Commercial Physical & Biological Research · Medical research